Infinitopes Adds Biotech Veterans to Board Amid Clinical Expansion
Infinitopes appoints biotech leaders Dan Menichella & Jo Brewer as it advances ITOP1, a vaccine for oesophageal cancer.
.webp&w=1920&q=75&dpl=dpl_DvHKTkTrxtw9jHK6MpkEndZCmmr3)
Infinitopes, a precision immuno-oncology company, has announced the appointment of Dan Menichella and Dr. Jo Brewer as Non-Executive Directors as it transitions into a clinical-stage company with its lead vaccine candidate, ITOP1, targeting oesophageal cancer. The appointments mark a strategic step in advancing next-generation cancer vaccines.
Dan Menichella brings deep expertise in biotech leadership, having driven high-value partnerships and strategic deals at CureVac and Bamboo Therapeutics. His track record includes securing billion-dollar collaborations with industry leaders like Eli Lilly, Biogen, and Takeda. With experience in fundraising, M&A, and corporate growth, Menichella is poised to help steer Infinitopes’ expansion and clinical progress.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Plus dans Pharma News
Tous les articles →
Medicus Pharma soumet à la FDA le protocole de Phase 2b/3 pour Teverelix
Fresenius Kabi reçoit une lettre d’avertissement de la FDA après des défaillances d’enquête sur le traitement aseptique dans l’établissement de Melrose Park
Discussion